Re: Muayad et al.: Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes (Ophthalmology. 2025;132:271-279)
Re: Ugradar et al.: The rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up (Ophthalmology. 2025;132:92-97)
Re: Matsunaga et al.: Disparities in amblyopia treatment outcomes: the impact of sociodemographic factors, treatment compliance, and age of diagnosis. (Ophthalmology. 2025;132:335-342)